Literature DB >> 7606340

Neuroprotective profile of lifarizine (RS-87476) in rat cerebrocortical neurones in culture.

G R May1, W S Rowand, J G McCormack, R D Sheridan.   

Abstract

1. The ability of the neuroprotective agent, lifarizine (RS-87476), to mitigate veratridine-, cyanide- and glutamate-induced toxicity in rat embryonic cerebrocortical neurones in primary culture has been compared with that of tetrodotoxin (TTX), nitrendipine, (+)-MK-801 and (-)-MK-801. Lactate dehydrogenase (LDH) released into the culture medium was used as the indicator of cell viability. 2. Incubation of cultures for 16 h in a medium containing veratridine (10(-4) M), sodium glutamate (10(-3) M) or sodium cyanide (10(-3) M) resulted in consistent elevations of LDH activity in the culture medium. The ability of compounds to attenuate these elevations was expressed as the concentration required to inhibit the increases in LDH release by 50% (IC50). 3. Neurotoxicity induced by veratridine was inhibited by lifarizine (IC50 = 4 x 10(-7) M), TTX (IC50 = 3 x 10(-8) M) and nitrendipine (IC50 = 3 x 10(-5) M). In contrast, (+)-MK-801 (up to 3 x 10(-5) M) was ineffective against this insult. 4. Glutamate-induced neurotoxicity was inhibited by (+)-MK-801 (IC50 = 1.4 x 10(-8) M) and to a lesser extent by (-)-MK-801 (IC50 = 1 x 10(-7) M), but was unaffected by lifarizine, TTX or nitrendipine (up to 10(-6) M). 5. (+)-MK-801 was effective against sodium cyanide-induced neurotoxicity (IC50 = 1.9 x 10(-8) M), whereas lifarizine and TTX (up to 10(-6) M) and nitrendipine (up to 3 x 10(-6) M) were without protective activity against this insult. 6. The results demonstrate that lifarizine potently protects rat cortical neurones in vitro against a neurotoxic insult that requires activation of sodium channels for its expression, and that the compound is ineffective against insults mediated by N-methyl-D-aspartate receptor activation. The weak efficacy of nitrendipine against veratridine-induced cell death argues against the involvement of L-type calcium channels in this insult. These data are consistent with the notion that the neuroprotective activity oflifarizine observed in vivo may be mediated by inhibition of neuronal sodium currents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606340      PMCID: PMC1510289          DOI: 10.1111/j.1476-5381.1995.tb13357.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Cerebral cation shifts in hypoxic-ischemic brain damage are prevented by the sodium channel blocker tetrodotoxin.

Authors:  G H Prenen; K G Go; F Postema; F Zuiderveen; J Korf
Journal:  Exp Neurol       Date:  1988-01       Impact factor: 5.330

2.  Effects of dihydropyridine calcium channel modulators on cardiac sodium channels.

Authors:  A Yatani; D L Kunze; A M Brown
Journal:  Am J Physiol       Date:  1988-01

3.  Nimodipine improves outcome when given after complete cerebral ischemia in primates.

Authors:  P A Steen; S E Gisvold; J H Milde; L A Newberg; B W Scheithauer; W L Lanier; J D Michenfelder
Journal:  Anesthesiology       Date:  1985-04       Impact factor: 7.892

4.  Block of human voltage-sensitive Na+ currents in differentiated SH-SY5Y cells by lifarizine.

Authors:  N A Brown; J A Kemp; G R Seabrook
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

5.  The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat.

Authors:  C K Park; D G Nehls; D I Graham; G M Teasdale; J McCulloch
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

6.  Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists.

Authors:  D W Choi; J Y Koh; S Peters
Journal:  J Neurosci       Date:  1988-01       Impact factor: 6.167

7.  21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia.

Authors:  W Young; J C Wojak; V DeCrescito
Journal:  Stroke       Date:  1988-08       Impact factor: 7.914

8.  21-Aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils.

Authors:  E D Hall; K E Pazara; J M Braughler
Journal:  Stroke       Date:  1988-08       Impact factor: 7.914

9.  Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil.

Authors:  B J Alps; C Calder; W K Hass; A D Wilson
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

10.  Anti-anginal arylalkylamines and sodium channels: [3H]-batrachotoxinin-A 20-alpha-benzoate and [3H]-tetracaine binding.

Authors:  M Grima; J Schwartz; M O Spach; J Velly
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

View more
  5 in total

1.  Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis.

Authors:  J K Callaway; P M Beart; B Jarrott; S F Giardina
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion.

Authors:  D E McBean; V Winters; A D Wilson; C B Oswald; B J Alps; J M Armstrong
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

3.  [3H]-lifarizine, a high affinity probe for inactivated sodium channels.

Authors:  A C MacKinnon; K M Wyatt; J G McGivern; R D Sheridan; C M Brown
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

4.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

5.  Inhibition by lifarizine of intracellular Ca2+ rises and glutamate exocytosis in depolarized rat cerebrocortical synaptosomes and cultured neurones.

Authors:  D C Budd; G R May; D G Nicholls; J G McCormack
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.